Myelodysplastic Syndromes
October 2020 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Chronic fatigue in myelodysplastic syndromes: Looking beyond anemia.
Authors:Brownstein CG, Daguenet E, Guyotat D, Millet GY
Institution:Univ Lyon, UJM-Saint-Etienne, Inter-University Laboratory of Human Movement Biology, EA 7424, F-42023, Saint-Etienne, France. Electronic address: callum.brownstein@univ-st-etienne.fr. Univ Lyon, UJM-Saint-Etienne, Inter-University Laboratory of Human Movement Biology, EA 7424, F-42023, Saint-Etienne, France; Institut Universitaire de France (IUF), France.
Journal:Crit Rev Oncol Hematol. 2020 Oct;154:103067. doi: 10.1016/j.critrevonc.2020.103067. Epub 2020 Jul 27.

2:Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Authors:Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, Chung SS, Rampal RK, Park JH, Stein EM, Tallman MS, Sen F, Gönen M, Abdel-Wahab O, Klimek VM
Institution:Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: klimekv@mskcc.org.
Journal:Lancet Haematol. 2020 Aug;7(8):e566-e574. doi: 10.1016/S2352-3026(20)30209-X.

3:Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes.
Authors:Alkhateeb HB, Patnaik MM, Al-Kali A, Zblewski DL, Wallerich S, McTavish H, Dudek AZ
Institution:Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Rochester, MN, U.S.A. IGF Oncology, LLC, Saint Paul, MN, U.S.A.
Journal:Anticancer Res. 2020 Jul;40(7):3883-3888. doi: 10.21873/anticanres.14378.

4:Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC.
Authors:Le Bourgeois A, Labopin M, Marçais A, de Latour RP, Blaise D, Chantepie S, N'Guyen S, Maillard N, Forcade E, Yakoub-Agha I, Huynh A, Marchand T, Bilger K, Ceballos P, Charbonnier A, Turlure P, Rubio MT, Béné MC, Guillaume T, Mohty M, Chevallier P
Institution:Department of Hematology, CHU Hotel Dieu, Place A. Ricordeau, 44093, Nantes Cedex, France. amandine.lebourgeois@chu-nantes.fr. Department of Hematology, CHU Hotel Dieu, Place A. Ricordeau, 44093, Nantes Cedex, France. patrice.chevallier@chu-nantes.fr.
Journal:Ann Hematol. 2020 Aug;99(8):1855-1862. doi: 10.1007/s00277-020-04074-7. Epub 2020 Jun 20.

5:Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
Authors:Navada SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian MN, John RB, Demakos EP, Zbyszewski PS, Maniar M, Woodman RC, Fruchtman SM, Silverman LR
Institution:Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029, United States. Electronic address: shyamala.na
Journal:Leuk Res. 2020 Jul;94:106369. doi: 10.1016/j.leukres.2020.106369. Epub 2020 May 12.

6:Alcohol use is not a significant contributor to myelodysplastic syndromes.
Authors:Duffy EA, Nguyen PL, Cioc A, Warlick E, Roesler MA, Poynter JN
Institution:Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA. Division of Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, 420 Delaware St. S.E., Minneapolis, MN, USA. poynt006@umn.edu.
Journal:Cancer Causes Control. 2020 Jun;31(6):549-557. doi: 10.1007/s10552-020-01298-w. Epub 2020 Apr 13.

7:Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of EBMT group.
Authors:Giardino S, de Latour RP, Aljurf M, Eikema DJ, Bosman P, Bertrand Y, Tbakhi A, Holter W, Bornhäuser M, Rössig C, Burkhardt B, Zecca M, Afanasyev B, Michel G, Ganser A, Alseraihy A, Ayas M, Uckan-Cetinkaya D, Bruno B, Patrick K, Bader P, Itälä-Remes M, Rocha V, Jubert C, Diaz MA, Shaw PJ, Junior LGD, Locatelli F, Kröger N, Faraci M, Pierri F, Lanino E, Miano M, Risitano A, Robin M, Dufour C
Institution:Hematopoietic stem cell transplantation Unit, Istituto Giannina Gaslini, Genoa, Italy. UOC Ematologia, Istituto Giannina Gaslini, Genoa, Italy.
Journal:Am J Hematol. 2020 Jul;95(7):809-816. doi: 10.1002/ajh.25810. Epub 2020 Apr 21.

8:Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.
Authors:Martinez-Høyer S, Deng Y, Parker J, Jiang J, Mo A, Docking TR, Gharaee N, Li J, Umlandt P, Fuller M, Jädersten M, Kulasekararaj A, Malcovati L, List AF, Hellström-Lindberg E, Platzbecker U, Karsan A
Institution:Michael Smith Genome Sciences Centre, BC Cancer Research Centre, Vancouver, British Columbia, Canada. akarsan@bcgsc.ca.
Journal:Nat Cell Biol. 2020 May;22(5):526-533. doi: 10.1038/s41556-020-0497-9. Epub 2020 Apr 6.

9:Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
Authors:Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW
Institution:Department of Pharmacy and Clinical Services, Hackensack University Medical Center, Hackensack, New Jersey, USA. Division of Hematology-Oncology/Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Journal:Am J Hematol. 2020 Jul;95(7):792-798. doi: 10.1002/ajh.25808. Epub 2020 May 4.

10:Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.
Authors:Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, Rodriguez MG, Dong X, Ghosh J, Izquierdo M, Garcia-Manero G
Institution:Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy (E.A.). MD Anderson Cancer Center, University of Texas, Houston, Texas (G.G.).
Journal:Ann Intern Med. 2020 Apr 21;172(8):513-522. doi: 10.7326/M19-0916. Epub 2020 Mar 24.

11:Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Authors:Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM
Institution:Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: steine@mskcc.org. Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Lancet Haematol. 2020 Apr;7(4):e309-e319. doi: 10.1016/S2352-3026(19)30284-4. Epub 2020 Mar 5.

12:How to treat myelodysplastic syndrome with clinical features resembling Behçet syndrome: a case-based systematic review.
Authors:Yilmaz U, Ar MC, Esatoglu SN, Bavunoglu I, Erzin YZ, Hatemi AI, Yildirim S, Hatemi G, Celik AF
Institution:Department of Internal Medicine, Division of Hematology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, 34098, Istanbul, Turkey. umutyza@hotmail.com. Department of Internal Medicine, Division of Gastroenterology, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Journal:Ann Hematol. 2020 Jun;99(6):1193-1203. doi: 10.1007/s00277-020-03951-5. Epub 2020 Mar 5.

13:Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Authors:Shabanova I, Cada M, Johnston DL, Abbott LS, Leung EW, Schechter T, Dror Y, Klaassen RJ
Institution:Genetics and Genome Biology Program. Department of Pediatrics, Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada.
Journal:J Pediatr Hematol Oncol. 2020 Apr;42(3):170-174. doi: 10.1097/MPH.0000000000001763.

14:Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Authors:Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Journal:Am J Hematol. 2020 Jun;95(6):612-622. doi: 10.1002/ajh.25769. Epub 2020 Mar 20.

15:Evolving therapies for lower-risk myelodysplastic syndromes.
Authors:Bewersdorf JP, Zeidan AM
Institution:Department of Medicine, Section of Hematology, Yale University, 333 Cedar Street, PO Box 208028, New Haven, CT, 06520-8028, USA. amer.zeidan@yale.edu.
Journal:Ann Hematol. 2020 Apr;99(4):677-692. doi: 10.1007/s00277-020-03963-1. Epub 2020 Feb 20.

16:TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
Authors:Ren Y, Wang J, Zhang H, Mei C, Ye L, Luo Y, Zhou X, Zhu S, Jiang L, Wang L, Jin J, Tong H
Institution:Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Journal:Asia Pac J Clin Oncol. 2020 Jun;16(3):172-179. doi: 10.1111/ajco.13316. Epub 2020 Feb 7.

17:Genetic Factors in Acute Myeloid Leukemia With Myelodysplasia-Related Changes.
Authors:Fang H, He R, Chiu A, Viswanatha DS, Ketterling RP, Patnaik MS, Reichard KK
Institution:Division of Hematopathology, Rochester, MN.
Journal:Am J Clin Pathol. 2020 Apr 15;153(5):656-663. doi: 10.1093/ajcp/aqz206.

18:Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Authors:Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I
Institution:University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. igojo1@jhmi.edu.
Journal:Leukemia. 2020 Jun;34(6):1563-1576. doi: 10.1038/s41375-019-0693-4. Epub 2020 Jan 3.

19:Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients.
Authors:Zhang Y
Institution:Department of Hematology, Eastern Branch of the Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, People's Republic of China.
Journal:Hematology. 2020 Dec;25(1):1-10. doi: 10.1080/16078454.2019.1700330.

20:An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring.
Authors:Starkman R, Alibhai S, Wells RA, Geddes M, Zhu N, Keating MM, Leber B, Chodirker L, Sabloff M, Christou G, Leitch HA, St-Hilaire E, Finn N, Shamy A, Yee K, Storring J, Nevill T, Delage R, Elemary M, Banerji V, Lenis M, Kirubananthaan A, Mamedov A, Zhang L, Rockwood K, Buckstein R
Institution:Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. rena.buckstein@sunnybrook.ca.
Journal:Leukemia. 2020 May;34(5):1394-1406. doi: 10.1038/s41375-019-0666-7. Epub 2019 Dec 6.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: July 7, 2020
179 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS83764687

Coupon Expires: November 24, 2020



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.